On 21 Aug I stuck my neck out to suggest that Selegeline may not be the wonder drug to save the world that some would have us believe. I promptly got my neck chopped off by a flood of references,each of which appeared to find some new and unexpected attribute of Selegiline. Now, in the very interesting post from Bruce Wallace of a radio interview with Prof. Olanow of the Mount Sinai School of Medicine in New York, comes a new slant on the story: If I have followed the interview correctly, he is saying (And he is a Selegiline supporter) that the two groups who showed such a marked difference in the early years, over a period of 5 to 10 years end up looking the same. In other words the 'protection' afforded by Selegiline is limited to the first few years, and over a 5 to 10 year period, both groups arrive at the same level of deterioration. Prof Olanow is convinced that, hiding inside the Selegiline is the real agent which can provide substantial neuro-protection, but it is not capable of working while trapped inside the Selegiline. So what is the score-card showing now: On the supporter's side there is the transitory benefit of a slower deterioration rate in the first few years (But do they suffer some PD symptoms- possibly minor?) On my side, we have apparently no real difference in the long run, plus the other worries, such as hallucinations in some people, wild dreams in some people, continuing concern that there may yet be an increased mortality risk, and a genuine danger if taken with the pain-killer Demerol (I think it is called Pethedine in the UK). I look forward to the next round !! Regards -- Brian Collins <[log in to unmask]>